, /PRNewswire/ — Zydus Lifesciences Ltd. (including its subsidiaries and affiliates), a global innovation-driven healthcare company, today announced that it has entered into an exclusive licensing and commercialization agreement with…
, /PRNewswire/ — Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today…
, /PRNewswire/ — mAIbe and LenioBio are pleased to announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation monoclonal antibodies. By combining mAIbe’s AI-driven…
In the relentless pursuit of optimizing care in neonatal intensive care units (NICUs), researchers have placed a spotlight on dexmedetomidine, a sedative that may redefine the standards of neonatal sedation.…
French vaccine developer Valneva is closing down a site that houses both operational and R&D work, impacting 30 employee roles. The biopharma is shuttering its location in Nantes, a spot…
TEL AVIV, Israel, Nov. 26, 2025 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc.,…
In a groundbreaking study that could reshape our understanding of environmental impacts on human health, researchers have unveiled compelling evidence that industrial and agricultural chemicals possess inherent antimicrobial properties against…
In a groundbreaking study that bridges the fields of neuroscience and oncology, researchers have unveiled critical insights into how primary brain cancers known as gliomas interweave with neural circuits, revealing…
GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members…
WALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participate in the 8th…